YDMI
REGN icon

Y.D. More Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Y.D. More Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28
Closed -$47 – 519
2025
Q3 		$47 Buy
+28
New +$15.8K ﹤0.01% 451

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Y.D. More Investments's REGN Position: Q4 2025 in Review

Y.D. More Investments sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 28 shares — an estimated $47 sold.

Y.D. More Investments first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $47 in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Y.D. More Investments reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Y.D. More Investments sold 28 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $47.
  • Y.D. More Investments first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Y.D. More Investments's Regeneron Pharmaceuticals position peaked at $47 in Q3 2025.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Y.D. More Investments's 13F filing for Q4 2025, filed 21 Jan 2026.